Top 10 Medicaid Specialty Therapy Drugs

Ranked By 2014 PMPY Spend

Rank Drug Name Therapy Class PMPY Spend % of Total Specialty Spend Utilization Trend Unit Cost Trend Total Trend
1 Sovaldi® (sofosbuvir) Hepatitis C
$43.13 17.6% 33131.0% -503.2% 32627.8%
2

Humira® (adalimumab)

Inflammatory Conditions $12.78 5.2% 11.4% 19.9% 31.3%
3 Enbrel® (etanercept)
Inflammatory Conditions $9.35 3.8% 10.4% 18.7% 29.2%
4

Atripla® (efavirenz/emtricitabine/tenofovir)

HIV $8.82 3.6% -7.4% 7.0% -0.3%
5

Truvada® (emtricitabine/tenofovir)

HIV $8.77 3.6% -0.5% 4.3% 3.8%
6

Copaxone® (glatiramer)

Multiple Sclerosis
$6.51 2.7% -11.7% 9.0% -2.7%
7 Viread® (tenofovir)
HIV
$5.58 2.3% -2.2% 4.0% 1.8%
8 Tecfidera® (dimethyl fumarate)
Multiple Sclerosis $5.19 2.1% 216.3% 31.4% 247.7%
9 Avonex® (interferon beta 1-a) Multiple Sclerosis $4.61 1.9% -28.4% 8.3% -20.1%
10 enoxaparin Anticoagulants
$4.32 1.8% 1.2% -13.0% -11.7%